From the resulting list of 17 putative targets, we chose to validate the N-acetyltransferase 2 (NAT2) enzyme as a candidate in colorectal cancer (CRC), as >20% patients lose a gene allele due to LOH.8 The NAT2 enzyme catalyzes the metabolism of xenobiotics through acetylation, and its expression is restricted to the liver and gastrointestinal tract. The gene discussed is NAT2; the disease is colorectal cancer.